Understanding how genes affect immune responses in lymphoma treatment
Integrative approach to identify genomic features that shape the immune landscape and predict immunotherapy response in diffuse large B cell lymphoma
['FUNDING_R01'] · UNIVERSITY OF CHICAGO · NIH-11079518
This study is looking at how the immune system interacts with diffuse large B cell lymphoma (DLBCL) to find out which genetic traits might help predict how well patients will respond to immunotherapy, so that treatments can be better tailored for those whose cancer has come back or hasn’t responded to other treatments.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UNIVERSITY OF CHICAGO (nih funded) |
| Locations | 1 site (CHICAGO, UNITED STATES) |
| Trial ID | NIH-11079518 on ClinicalTrials.gov |
What this research studies
This research investigates the immune landscape of diffuse large B cell lymphoma (DLBCL) to identify genomic features that may predict how well patients respond to immunotherapy. By analyzing gene expression in tumor samples, the study aims to classify the immune environment as either 'inflamed' or 'non-inflamed', which can influence treatment outcomes. The research will utilize advanced techniques to explore the relationship between genetic alterations in cancer cells and the immune response, potentially guiding personalized treatment strategies for patients with relapsed or refractory DLBCL.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with relapsed or refractory diffuse large B cell lymphoma.
Not a fit: Patients with other types of lymphoma or those who are not relapsed or refractory may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved identification of patients who are likely to benefit from immunotherapy, enhancing treatment outcomes.
How similar studies have performed: Previous research has shown promise in characterizing immune landscapes in other cancers, suggesting potential for success in this approach for DLBCL.
Where this research is happening
CHICAGO, UNITED STATES
- UNIVERSITY OF CHICAGO — CHICAGO, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: KLINE, JUSTIN P. — UNIVERSITY OF CHICAGO
- Study coordinator: KLINE, JUSTIN P.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.